Oleuropein as a novel anti-diabetic nutraceutical. An overview

Volume 1 - Issue 3

Giuseppe Annunziata¹*, Maria Maisto¹, Connie Schisano¹, Luigi Barrea², Roberto Ciampaglia¹, Viviana Narciso¹, Gian Carlo Tenore¹ and Ettore Novellino¹

Received: August 25, 2018;   Published: August 28, 2018

DOI: 10.32474/ADO.2018.01.000113

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Among the cardiometabolic diseases, type 2 diabetes mellitus (T2DM) is one of the most diffused worldwide. Pharmacological treatments commonly used present several side effects, and this is driving people to search natural approaches. Olea europaea is currently investigated for its anti-diabetic potential. In particular, oleuropein (OLE), its main bioactive compound, have been demonstrated to exert interesting activities in management of T2DM, including hypoglycemic and antioxidant activities. The purpose of this manuscript is to review the available scientific evidence evaluating the role of OLE in managing T2DM.

Keywords: Oleuropein; Type 2 Diabetes; Glucose Homeostasis; Oxidative Stress; Antioxidant

Abbreviations: T2DM: Type 2 Diabetes Mellitus; CVD: Cardiovascular Disease; AMPK: Amp- Activated Protein Kinase; OLE: Oleuropein; SGLT1: Sodium-Dependent Glucose Transporter; EFSA: European Food Safety Authority; IGT: Impaired Glucose Tolerance: TSOD: Tsumura Suzuki Obese Diabetes; GLUT: Glucose Transporter; ROS: Reactive Oxygen Species; RNS: Reactive Nitrogen Species; MDA: Malondialdehyde; HT: Hydroxytyrosol

Abstract| Introduction| Oleuropein: from chemistry to biology| Anti-diabetic effects of oleuropein| Conclusion and future perspectives| References|